Pharmaceutical care of a child with high-risk neuroblastoma using dinutuximab beta by clinical pharmacists

Published on Aug. 31, 2023Total Views: 2017 times Total Downloads: 1263 times Download Mobile

Author: Li-Ting YU ¹ Zhuo WANG ² Yi-Jin GAO ² Shun-Guo ZHANG ¹  Ying-Zhong HE ³

Affiliation: 1. Department of Pharmacy, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China 2. Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China 3. Department of Neurology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

Keywords: Neuroblastoma Dinutuximab beta Adverse drug reaction Pain Pharmaceutical care

DOI: 10.19960/j.issn.1005-0698.202310010

Reference: Li-Ting YU, Zhuo WANG, Yi-Jin GAO, Shun-Guo ZHANG, Ying-Zhong HE.Pharmaceutical care of a child with high-risk neuroblastoma using dinutuximab beta by clinical pharmacists[J].Yaowu Liuxingbingxue Zazhi,2023, 32(10):1170-1174.DOI: 10.19960/j.issn.1005-0698.202310010.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Clinical pharmacists performed pharmaceutical care for a child with high-risk neuroblastoma who was treated with dinutuximab beta to explore the role of clinical pharmacists in new targeted drug therapy. Adverse reactions such as pain, repeated high fever (heat peak 40℃), capillary leakage syndrome (eyelid edema, reduced blood pressure), diarrhea, hypokalemia (2.74 mmol·L^-1), vomiting occurred successively during the use of dinutuximab beta. The clinician gave the patient symptomatic treatments such as analgesic, antipyretic, anti-infection, diuretic, antidiarrhea, potassium supplement and antiemesis, etc. The clinical pharmacist put forward suggestions on the usage, dosage and dose adjustment of dinutuximab beta, analgesic drug (morphine, gabapentin), antibiotics (cefoperazone sulbactam, voriconazole), antiemesis drug (palonosetron) and other drugs, which were adopted by the clinic. The effectiveness and safety of medication for children were improved.

Full-text

Please download the PDF version to read the full text: download

References

1.鲍萍萍, 李凯, 吴春晓, 等. 2002-2010年上海市户籍儿童恶性实体肿瘤发病特征和变化趋势分析[J].

中华儿科杂志, 2013, 51(4): 288-294. [Bao PP, Li K, Wu CX, et al. Analysis on the incidence and change trend of malignant solid tumors in children registered in Shanghai from 2002 to 2010[J]. Chinese Journal of Pediatrics, 2013, 51(4): 288-294.] DOI: 10.3760/cma.j.issn.0578-1310.2013.04.010.

2.Liang WH, Federico SM, London WB, et al. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future[J]. JCO Clin Cancer Inform, 2020, 4: 895-905. DOI: 10.1200/CCI. 20.00074.

3.Pastor ER, Mousa SA. Current management of neuroblastoma and future direction[J]. Crit Rev Oncol Hematol, 2019, 138: 38-43. DOI: 10.1016/j.critrevonc. 2019.03.013.

4.Gains J, Mandeville H, Cork N, et al. Ten challenges in the management of neuroblastoma[J]. Future Oncol, 2012, 8(7): 839-858. DOI: 10.2217/fon.12.70.

5.GD2单抗治疗神经母细胞瘤临床应用协作组. GD2抗体达妥昔单抗β治疗神经母细胞瘤的临床应用专家共识(2021年版)[J]. 临床儿科杂志, 2022, 40(1): 14-20. DOI: 10.12372/ jcp. 2022. 21e1685.

6.Mody R, Naranjo A, van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2017, 18(7): 946-957. DOI: 10.1016/S1470-2045(17)30355-8.

7.Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management[J]. Kidney Int, 2017, 92(1): 37-46. DOI: 10.1016/j.kint.2016. 11.029.

8.中华医学会血液学分会, 中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2016年版)[J]. 中华血液学杂志, 2016, 37(5): 353-359. DOI: 10.3760/cma.j.issn.0253-2727. 2016.05.001.

9.Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma[J]. Cancer Invest, 2007, 25(1): 67-77. DOI: 10.1080/07357900601130763.

10.Mujoo K, Cheresh DA, Yang HM, et al. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth[J]. Cancer Res, 1987, 47(4): 1098-1104. https://pubmed.ncbi.nlm.nih.gov/3100030/.

11.Cheung NK, Saarinen UM, Neely JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells[J]. Cancer Res, 1985, 45(6): 2642-2649. https://pubmed.ncbi.nlm.nih.gov/2580625/.

12.Siebert N, Eger C, Seidel D, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2[J]. MAbs, 2016, 8(3): 604-616. DOI: 10.1080/19420862.2015.1130196.

13.Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334. DOI: 10.1056/NEJMoa0911123.

14.Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO[J]. MAbs, 2018, 10(1): 55-61. DOI: 10.1080/19420862.2017.1402997.

15.Barone G, Barry A, Bautista F, et al. Managing adverse events associated with dinutuximab beta treatment in patients with high-risk neuroblastoma: practical guidance[J]. Paediatr Drugs, 2021, 23(6): 537-548. DOI: 10.1007/s40272-021-00469-9.